Ken Horne
Ken Horne is an experienced healthcare investor, entrepreneur, and executive with over two decades of professional success. He currently serves as the Managing Partner of AN Ventures, a US-Japan focused biotech fund. He additionally serves in board leadership and advisory capacities across several biotechnology companies, including Typewriter Therapeutics, Capacity Bio, Imbria Pharmaceuticals, Nocicera, Pahr Therapeutics, Ando Therapeutics, Kan Therapeutics, and En Biotherapeutics.
Previously, he was the chairperson of RDiscovery, Remiges Ventures’ company creation entity. As an entrepreneur, he co-founded or led Aline Aesthetics (acquired by Allergan), Symic Bio (acquired by Nordic Bio), and Teon Therapeutics. Before that, he was a founding member of TauTona Group, an early-stage life science venture capital fund backed by Stanford Management Company and others. He started his career working for The Foundry, a preeminent medtech incubator, and he was an early or founding employee at eValve (acquired by Abbott), Cierra (acquired by Terumo), and others.
Ken holds a BS and MS from Stanford University in Mechanical Engineering. As a Kauffman Fellow (Class 17), he was honored with the Jeff Timmons Leadership Award.